QM球盟会(中国)有限公司

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

09-152025

Bio-Thera Strikes Strategic Deal with Jamjoom Pharma for Securing Cosentyx® Biosimilar in MENA

Guangzhou, China / Jeddah, Saudi Arabia – September 15,2025 –Bio-Thera Solutions Inc.(688177:SH), a commercial-stage bio...
09-112025

Medicines and Healthcare products Regulatory Agency (MHRA) Approves Bio-Thera Solutions’ Qletli® (adalimumab), a biosimilar referencing Humira®

Guangzhou,China– September 10, 2025 –Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company de...
08-262025

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

上一页 ···2 3 4 5 6 ··· 下一页